Glucosio Con Potassio Cloruro I Bioindustria L.I.M. (Potassium Chloride, Glucose Monohydrate)

Glucosio Con Potassio Cloruro I is indicated for clinical situations where rapid restoration of potassium and fluid balance is required. It is commonly employed in the following contexts:

• Treatment of hypokalemia or potassium depletion.
• Fluid replacement therapy after surgery or trauma.
• Management of electrolyte disturbances during acute illness.
• Support during postoperative recovery when potassium losses are anticipated.
• Adjunct to intravenous nutrition regimens that lack adequate potassium.
• Emergency care for patients with severe electrolyte imbalance.

Side effects may vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common

• Mild injection site irritation or pain.
• Transient nausea or vomiting.
• Temporary hyperglycemia.
• Slight increase in serum potassium that resolves spontaneously.

Serious

• Severe hyperkalemia leading to cardiac arrhythmia.
• Anaphylactic or severe allergic reaction.
• Significant electrolyte disturbances (e.g., hypernatremia).
• Phlebitis or thrombophlebitis at the infusion site.

Before using Glucosio Con Potassio Cloruro I, clinicians should consider several safety factors. Appropriate assessment helps minimize risk:

• Verify baseline serum potassium, glucose, and renal function.
• Adjust dose in patients with renal insufficiency or heart failure.
• Use caution in individuals with diabetes or impaired glucose tolerance.
• Avoid rapid infusion rates that may cause cardiac irritation.
• Monitor cardiac rhythm in patients at risk for arrhythmias.
• Discontinue if signs of severe hyperkalemia develop.
• Ensure aseptic technique to prevent infection.

Glucosio Con Potassio Cloruro I can interact with other medications that affect potassium balance or glucose metabolism.

Avoid

• Concurrent use of other potassium supplements or potassium‑sparing diuretics without monitoring.
• Co‑administration with insulin or insulin secretagogues without glucose monitoring.
• Simultaneous infusion of high‑dose calcium gluconate, which may precipitate potassium.

Use with caution

• ACE inhibitors, ARBs, or NSAIDs that may alter renal potassium handling.
• Beta‑blockers that can mask hypoglycemia symptoms.
• Digoxin, as altered potassium levels can affect its toxicity.
• Loop diuretics, which may exacerbate potassium loss.
• Corticosteroids, which can influence glucose levels.